🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The Alumis team is at Maui Derm Hawaii! Stop by our booth & check out our poster presentations to learn about ESK-001, an oral TYK2i currently in the Phase 3 ONWARD clinical program for the treatment of moderate-to-severe plaque psoriasis. For more info:  bit.ly/3C5oyE5

Congrats to Jack Danilkowicz, joining Alumis as Chief Commercial Officer, bringing extensive biopharma experience successfully planning and executing commercial strategies, and to Sara Klein on her promotion to Chief Legal Officer. Learn more: bit.ly/4gcaHK0 $ALMS

We are excited to announce our merger with @ACELYRIN, INC. This is an important step forward for Alumis to advance our highly differentiated late-stage portfolio to improve the lives of patients with immune-mediated diseases. Read more here: bit.ly/42KSY9j

Our CEO, Martin Babler, will present today at OPCO's 35th Annual HC Life Sciences Conf at 3:20 pm ET. Watch live to learn about our highly differentiated late-stage portfolio of investigational treatments for immune-mediated diseases: bit.ly/3QehKHx #OPCOLifeSciences

We’re on the ground at #ACTRIMSForum 2025 excited for tomorrow’s poster presentations that support our plan to begin a Phase 2 clinical trial of oral TYK2 inhibitor A-005 in patients with MS in the second half of this year. Learn more: bit.ly/41f8zM9

Today, we announced four data presentations at #AAD2025, including a late-breaker of 52-week data from the Phase 2 OLE study of ESK-001 in psoriasis, and that we have accelerated the topline Phase 3 data readout to Q1 2026. Read more: bit.ly/4kk4wXu

On the heels of #ACTRIMSForum and at the start of #MSAwarenessMonth, we are feeling inspired by the innovation occurring within the MS community and are proud to help foster advancements in clinical care. Check out our poster presentations here: bit.ly/4ePa5JT

We're shaking things up in psoriasis at #AAD2025! Stop by BOOTH #952 for a milkshake and to learn about our next-generation TYK2 inhibitor, the unmet needs we aim to address, and Alumis. We hope to see you there!

Late-breaking data presented at #AAD2025 demonstrate ESK-001’s robust clinical responses for the potential treatment of psoriasis through week 52, including patients’ reported symptoms and quality of life. Learn more: bit.ly/3F6bGyn

Our CEO, Martin Babler, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 10:40 EST today. Catch the presentation live at: investors.alumis.com/news-events/ev…

That’s a wrap #AAD2025! Thanks to all who attended Dr. Andy Blauvelt’s late-breaker on ESK-001 and those who visited our booth to learn how we’re shaking up PsO treatment with our next-generation TYK2i. If you haven't seen it yet, check out this video: bit.ly/3DxaPGy

Today we reported our year end 2024 financial results and provided a summary of recent corporate achievements and upcoming milestones. Learn more: bit.ly/3DU0TqW

Today, we announced a collaboration and licensing agreement with Kaken Pharmaceutical, a dermatology leader with significant reach and expertise in the Japanese market, for ESK-001 for dermatology indications in Japan. Learn more about the deal here: bit.ly/4j51CEN $ALMS

Check it out: Dermatology Times sat down with our CMO, Jörn Drappa, to discuss the 52-week ESK-001 Phase 2 OLE data presented at #AAD2025 and its potential in plaque PsO.

Kicking off #LupusAwarenessMonth with ESK-001 data for Systemic Lupus Erythematosus (SLE) at the Congress of Clinical Rheumatology East. Learn more: bit.ly/3DxaPGy

Come join us at #SIDSanDiego25, where we'll present data on ESK-001 for plaque psoriasis through both an oral and a poster presentation. Learn more: bit.ly/3DxaPGy

Today, we reported our Q1 2025 financial results and summarized recent corporate achievements. Learn more: bit.ly/4jTWALQ

Today, we announced the completion of our merger with ACELYRIN. With a differentiated portfolio of drug candidates and a strong balance sheet, we are well-positioned to drive innovation and deliver transformative treatments for immune-mediated diseases. Learn more:

Patient enrollment in our pivotal Phase 3 ONWARD clinical program evaluating ESK-001 for moderate-to-severe plaque psoriasis is now complete, with topline results expected in early Q1 2026. Learn more: bit.ly/3HhZQ5q

Today we announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference. Mark your calendar and catch the live webcast or access the replay: investors.alumis.com/news-events/ev…